Einstein researchers lead panels at NIH Aging and Chronic Disease Symposium on Geroscience

(Press-News.org) Contact information: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Einstein researchers lead panels at NIH Aging and Chronic Disease Symposium on Geroscience October 29, 2013 – (BRONX, NY) – The National Institutes of Health (NIH) has chosen two leading aging researchers at Albert Einstein College of Medicine of Yeshiva University to chair panels at the first symposium on "geroscience"—the study of how aging influences the onset of chronic diseases.

Aging is a major risk factor for major chronic diseases including cancer, cardiovascular disease and diabetes. Understanding the biological processes that underlie aging could lead to new ways of treating or even preventing chronic disease.

The NIH symposium is the first to take an integrated approach to studying diseases associated with aging. Each of its seven panels will focus on a different broad area of research: inflammation, adaption to stress, epigenetics, metabolism, macromolecular damage, proteostasis and adult stem cells and regeneration.

Jeffrey Pessin, Ph.D., director of Einstein's Diabetes Research Center, and Christopher Newgard, Ph.D., of Duke University School of Medicine, will co-chair the panel on metabolism and how making it more efficient could help fight age-related diseases processes. Dr. Pessin holds the Judy R. and Alfred A. Rosenberg Professorial Chair in Diabetes Research and is professor of medicine and of molecular pharmacology at Einstein.

Ana Maria Cuervo, M.D., Ph.D., co-director of Einstein's Institute for Aging Research, will co-chair the panel on proteostasis with Richard Morimoto, Ph.D., of Northwestern University. Proteostasis involves preserving cell function by preventing cell proteins from either degrading or accumulating as we age. Dr. Cuervo is professor of developmental and molecular biology, of anatomy and structural biology, and of medicine and holds the Robert and Renee Belfer Chair for the Study of Neurodegenerative Diseases.

Two other Einstein researchers will make presentations at the summit: Dongsheng Cai, M.D., Ph.D.: "Hypothalamic neurodegeneration: a common link between metabolic disease and aging Jan Vijg, Ph.D.: "Does DNA damage or mutations ever rise to high enough frequencies to directly cause functional decline?"

Featuring National Institutes of Health (NIH) director Francis Collins, the "Advances in Geroscience: Impact on Healthspan and Chronic Disease" scientific summit was organized by the trans-NIH Geroscience Interest Group (GSIG) with support from the Alliance for Aging Research and The Gerontological Society of America. Among the largest trans-NIH interest groups, the GSIG focuses on the relationships between aging and age-related disease and disability. More information and the Summit's agenda are available here.

### About Albert Einstein College of Medicine of Yeshiva University Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. During the 2013-2014 academic year, Einstein is home to 734 M.D. students, 236 Ph.D. students, 106 students in the combined M.D./Ph.D. program, and 353 postdoctoral research fellows. The College of Medicine has more than 2,000 full-time faculty members located on the main campus and at its clinical affiliates. In 2013, Einstein received more than $155 million in awards from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore Medical Center (http://www.montefiore.org/), the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Through its extensive affiliation network involving Montefiore, Jacobi Medical Center–Einstein's founding hospital, and five other hospital systems in the Bronx, Manhattan, Long Island and Brooklyn, Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States. For more information, please visit http://www.einstein.yu.edu and follow us on Twitter @EinsteinMed. END